On Feb 26, 2026, Cowen & Co. maintained its Buy on PROCEPT BioRobotics Corporation (PRCT), the headline in this PRCT analyst rating update. Cowen described itself as “constructive after the big stock decline,” keeping the buy stance despite a recent earnings shortfall and pressure on the shares.

This update matters because Cowen’s view anchors the near-term analyst consensus for PRCT and sets a public price target that investors watch closely. We review the Cowen action, the cited $34 price target reported by market sources, the stock reaction, and what this PRCT analyst rating means for investors now.

PRCT analyst rating: Cowen maintains Buy on Feb 26, 2026

Cowen & Co. formally maintained a Buy rating on PRCT on Feb 26, 2026, citing constructive signs after the stock’s recent decline. Cowen left its stance intact to signal confidence in the company’s commercial recovery despite near-term revenue weakness. StreetInsider report provides the firm’s commentary.

What Cowen said and the PRCT price target

Cowen’s commentary emphasized constructive outlook after shares dropped; market reporting ties Cowen’s view to a $34 price target. The $34 target appears in recent coverage and serves as Cowen’s benchmark for upside versus today’s market price. Investing.com coverage references that price target and the firm’s rationale.

How the rating connects to recent PRCT stock performance

PRCT shares declined after the company reported revenue of $76.1 million versus expectations of $93.77 million, a shortfall that helped trigger a roughly 12% move at the time. Cowen’s maintained Buy communicates that the firm sees value after that pullback, linking the rating directly to the recent price dip rather than fresh bullish data.

Analyst coverage history and other firm actions

Analyst coverage of PRCT is concentrated among a handful of firms; Cowen’s move is the most recent high-profile reiteration. Separately, other firms including Truist have adjusted forecasts or price targets, with Truist cutting its price target amid lower guidance. These mixed signals show active but selective coverage for PROCEPT BioRobotics Corporation.

What the PRCT analyst rating means for investors

A maintained Buy means the analyst believes the stock offers upside from current levels, not that immediate operational issues are resolved. Investors should view Cowen’s stance as a conviction on medium-term recovery against short-term revenue misses. Use the rating alongside earnings trends, adoption metrics for the AquaBeam system, and cash runway details before deciding.

Meyka AI grade and model view on PRCT

Meyka AI rates PRCT with a grade of B+. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s model is an AI-powered market analysis platform that complements analyst ratings but does not replace individual due diligence.

Final Thoughts

Cowen’s decision to maintain a Buy on PRCT on Feb 26, 2026 keeps a major analyst voice firmly positive despite a recent revenue miss and share weakness. The reiterated Buy, paired with a $34 price target cited in market coverage, signals that Cowen sees more upside than downside from current levels, framing the PRCT analyst rating as a vote of confidence in recovery rather than a reaction to short-term misses. Investors should interpret the maintained Buy as one input among many: combine the Cowen view with updated quarterly results, adoption rates for the AquaBeam Robotic System, and cash-flow guidance. Meyka AI rates PRCT with a grade of B+, which integrates analyst sentiment, sector comparisons, and financial metrics. These grades are not guarantees and are not financial advice; they are tools to help weigh Cowen’s maintained Buy against other data points before making investment decisions.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Analyst ratings are opinions and not guarantees of future performance. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.